EUVIMEDEUVIMED entdecken
Open Access

Cynarin as a potent anti‑osteolytic agent: Targeting MAPK and Nrf2‑Keap1 pathways for osteoclast inhibition and bone protection

Rui Chao, Yexin Wang, Zhan Liu, Tianhao Wan, Yi Mao, Xinru Xie, Lei Sun, Weifeng Xu, Xuzhuo Chen, Shanyong Zhang

International Journal of Molecular Medicine · 2025

DOI: 10.3892/ijmm.2025.5647 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Medicine, 2025. Verfasst von Rui Chao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Osteoclasts, Kelch-Like ECH-Associated Protein 1, Osteolysis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory bone resorption, especially bone loss caused by the abnormal activation of osteoclasts (OCs), has become an increasing health concern. As a natural anti‑inflammatory compound, cynarin has shown potential in the treatment of various inflammatory diseases; however, its role in inflammatory bone resorption remains to be investigated. The present study aimed to explore the therapeutic potential of cynarin in inflammatory bone resorption by focusing on its regulatory effects on OC differentiation, inflammatory responses and related signalling pathways. Our results showed that cynarin significantly inhibited bone resorption, reduced tartrate‑resistant acid phosphatase activity, and downregulated key OC differentiation markers (Atp6v0d2, Nfatc1, Dcstamp and Ctsk). RNA sequencing and western blot analyses revealed that cynarin inhibited mitogen‑activated protein kinase (MAPK) pathway activation, and that the MAPK‑specific activator anisomycin reversed this inhibitory effect. In addition, cynarin alleviated the inflammatory response by reducing reactive oxygen species levels and inhibiting the expression of inflammatory cytokines. More importantly, cynarin activated Nrf2 and enhanced the expression of antioxidant genes (Hmox and Cat). Micro‑computed tomography analysis revealed that cynarin significantly enhanced the bone structure in mice, as indicated by increased bone volume and trabecular number, and trabecular thickness. Histological analysis confirmed that cynarin inhibited the expression of OC markers (tartrate‑resistant acid phosphatase, receptor activator of nuclear factor κB and cathepsin K) and inflammatory factors (tumor necrosis factor‑alpha and inducible nitric oxide synthase), while promoting osteogenic markers (osteocalcin and RUNX2). Finally, cynarin‑treated mice showed enhanced Nrf2 nuclear translocation and inhibition of MAPK signalling. These findings revealed the multiple roles of cynarin in the treatment of inflammatory osteolysis and provided insights into its potential therapeutic mechanisms and targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NF-E2-Related Factor 2OsteoclastsKelch-Like ECH-Associated Protein 1OsteolysisMAP Kinase Signaling SystemAnimalsMiceBone ResorptionMaleSignal TransductionCell DifferentiationOsteogenesisRAW 264.7 CellsMitogen-Activated Protein Kinases

Stichwörter der Autor:innen

MAPKNrf2cynarininflammationosteoclastogenesisosteolysis

Substanzen

NF-E2-Related Factor 2Kelch-Like ECH-Associated Protein 1Nfe2l2 protein, mouseKeap1 protein, mouseMitogen-Activated Protein Kinases

Autor:innen und Institutionen

  • Department of Oral Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China.
  • Department of Stomatology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230601, P.R. China.

Zitieren

APA

Chao, R., Wang, Y., Liu, Z., Wan, T., Mao, Y., Xie, X., Sun, L., Xu, W., Chen, X., & Zhang, S. (2025). Cynarin as a potent anti‑osteolytic agent: Targeting MAPK and Nrf2‑Keap1 pathways for osteoclast inhibition and bone protection. International Journal of Molecular Medicine. https://doi.org/10.3892/ijmm.2025.5647

Vancouver

Chao R, Wang Y, Liu Z, Wan T, Mao Y, Xie X, et al. Cynarin as a potent anti‑osteolytic agent: Targeting MAPK and Nrf2‑Keap1 pathways for osteoclast inhibition and bone protection. International Journal of Molecular Medicine. 2025. doi:10.3892/ijmm.2025.5647

BibTeX
@article{Chao2025,
  author = {Chao, Rui and Wang, Yexin and Liu, Zhan and Wan, Tianhao and Mao, Yi and Xie, Xinru and Sun, Lei and Xu, Weifeng and Chen, Xuzhuo and Zhang, Shanyong},
  title = {Cynarin as a potent anti‑osteolytic agent: Targeting MAPK and Nrf2‑Keap1 pathways for osteoclast inhibition and bone protection},
  journal = {International Journal of Molecular Medicine},
  year = {2025},
  doi = {10.3892/ijmm.2025.5647}
}
Kostenlos starten →